{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:19:41Z","timestamp":1648678781817},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1007\/s00108-005-1365-1","type":"journal-article","created":{"date-parts":[[2005,2,18]],"date-time":"2005-02-18T10:15:52Z","timestamp":1108721752000},"page":"466-468","source":"Crossref","is-referenced-by-count":0,"title":["Effekte der RALE-Studie"],"prefix":"10.1007","volume":"46","author":[{"given":"E.","family":"Erdmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","volume":"42","author":"Domanski","year":"2003","unstructured":"Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E (2003) Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVED). J Am Coll Cardiol 42: 705?708","journal-title":"J Am Coll Cardiol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdanie MM, Lee DS et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543?551","journal-title":"N Engl J Med"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"2003","author":"Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003: 1309?1321","journal-title":"N Engl J Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709?717","journal-title":"N Engl J Med"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"Weber","year":"2001","unstructured":"Weber KT (2001) Aldosterone in congestive heart failure. N Engl J Med 345: 1689?1697","journal-title":"N Engl J Med"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","volume":"327","author":"Wrenger","year":"2003","unstructured":"Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH (2003) Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 327: 147?149","journal-title":"BMJ"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-005-1365-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1365-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:11:30Z","timestamp":1558584690000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-005-1365-1"}},"subtitle":["Hyperkali\ufffdmie nach Spironolactontherapie"],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s00108-005-1365-1","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}